Francesco Maura

BCL10 Gain-of-Function Impairs Germinal Center Participation by Naive B Cells and Cooperates with BCL6 to Drive Extrafollicular Diffuse Large B-Cell Lymphoma

This study shows BCL10 gain-of-function mutations prevent naive B cells from entering germinal centers and cooperate with BCL6 to cause extrafollicular diffuse large B-cell lymphoma.

The cyclin-G associated kinase (GAK) is a novel mitotic kinase and therapeutic target in diffuse large B-cell lymphoma

This paper identifies GAK as a novel mitotic kinase and therapeutic target in DLBCL, showing that GAK inhibition causes mitotic defects and that existing drugs can be repurposed for its targeting.

Lymphoma response to chimeric antigen receptor T cell therapy is driven by endogenous tumor-reactive CD8⁺ T cells

This study shows that durable CAR-T therapy in lymphoma requires cooperation with endogenous CD8 T cells, and tumors lacking MHC class I or CD58 resist treatment.

Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma

The paper identifies genomic and transcriptional changes in multiple myeloma cells that drive resistance to anti-BCMA therapies, termed 'plasma cell identity escape'.

Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma

This study analyzes whole-genome sequencing data from multiple myeloma patients to show that the timing of genetic events, not just their presence, affects clinical outcomes.

NRF2 translation block by inhibition of cap-dependent initiation sensitizes lymphoma cells to ferroptosis and CAR-T immunotherapy

This study shows that inhibiting cap-dependent translation in lymphoma cells increases sensitivity to ferroptosis and CAR-T therapy by reducing NRF2 expression.

CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myeloma.

This study identifies biallelic CD38 loss as a mechanism of resistance to anti-CD38 antibodies in multiple myeloma, with specific mutations affecting antibody efficacy.

RHOA Deletion Downregulates CD19 and Promotes Dysfunctional Immune Microenvironments in CAR-T Resistant B-Cell Lymphoma

Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignancies

The paper investigates the mutagenic impact of radiotherapy in hematologic malignancies and finds that RT contributes to the ID8 mutational signature, which is associated with treatment resistance and relapse.

Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapies

The paper shows that genomic antigen escape mechanisms in multiple myeloma occur during CAR-T/TCE treatment, not pre-existing, and emerge after one year of therapy.

Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma.

This study identifies genomic and immune factors associated with resistance to anti-CD38 therapy in multiple myeloma patients.

Copy number signatures predict chromothripsis and associate with poor clinical outcomes in patients with newly diagnosed multiple myeloma

This study shows copy number signatures predict chromothripsis in multiple myeloma and link to poor clinical outcomes using whole genome and exome sequencing data.

Genome-wide mutational signatures of immunological diversification in normal lymphocytes

The paper analyzes the mutational landscape of normal lymphocytes, revealing off-target effects of programmed genome engineering and the impact of differentiation and microenvironment exposure.

Revealing the impact of recurrent and rare structural variants in multiple myeloma

This study identifies 100 SV hotspots and 31 new candidate driver genes in multiple myeloma, revealing that 63% of SVs remain unexplained and are associated with outlier gene expression.

Pan-cancer analysis of whole genomes reveals driver rearrangements promoted by LINE-1 retrotransposition in human tumours

The paper analyzes somatic retrotransposition events in 2,954 cancer genomes, identifying L1 insertions as significant contributors to structural variations and oncogenesis.

An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures

This study identifies two molecular subgroups of anaplastic meningioma with distinct survival outcomes and links them to specific genetic mutations.